Use of fertility drugs and risk of ovarian cancer

Current Opinion in Obstetrics and Gynecology

Volumn 26, Issue 3, 2014, Pages 125-129

  Diergaarde, Brenda ^a   Kurta, Michelle L ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

fertility drugs; infertility; ovarian cancer; risk

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; FERTILITY PROMOTING AGENT; FOLLITROPIN; GONADORELIN; HUMAN MENOPAUSAL GONADOTROPIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; CLOMIFENE; ESTROGEN; GONADOTROPIN;

CANCER RISK; DRUG EXPOSURE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLOW UP; GENE MUTATION; HUMAN; NULLIGRAVIDA; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; ADULT; CASE CONTROL STUDY; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; INFERTILITY, FEMALE; METABOLISM; MUTATION; OVARIAN NEOPLASMS; OVULATION INDUCTION; PARITY; PREGNANCY; RISK FACTOR; TIME;

ADULT; CASE-CONTROL STUDIES; CLOMIPHENE; ESTROGENS; FEMALE; FERTILITY AGENTS, FEMALE; GENES, BRCA1; GENES, BRCA2; GONADOTROPINS; HUMANS; INFERTILITY, FEMALE; MUTATION; OVARIAN NEOPLASMS; OVULATION INDUCTION; PARITY; PREGNANCY; RISK FACTORS; TIME FACTORS;

EID: 84900391591     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000060     Document Type: Review

References (56)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2013; 63:11-30.
2. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975-2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
3. Wysowski DK. Use of fertility drugs in the United States, 1973 through 1991. Fertil Steril 1993; 60:1096-1098.
4. Titus-Ernstoff L, Perez K, Cramer DW, et al. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 2001; 84:714-721.
5. Vachon CM, Mink PJ, Janney CA, et al. Association of parity and ovarian cancer risk by family history of breast or ovarian cancer in a population-based study of postmenopausal women. Epidemiology 2002; 13:66-71.
6. Tung KH, Goodman MT, Wu AH, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003; 158:629-638.
7. Braem MG, Onland-Moret NC, van den Brandt PA, et al. Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol 2010; 172:1181-1189.
8. Tsilidis KK, Allen NE, Key TJ, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2011; 105:1436-1442.
9. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994; 140:585-597.
10. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004; 82:405-414.
11. Mosgaard BJ, Lidegaard O, Andersen AN. The impact of parity, infertility and treatment with fertility drugs on the risk of ovarian cancer. A survey. Acta Obstet Gynecol Scand 1997; 76:89-95.
12. Tworoger SS, Fairfield KM, Colditz GA, et al. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 2007; 166:894-901.
13. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371:303-314.
14. Siskind V, Green A, Bain C, Purdie D. Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 2000; 11:106-110.
15. Ness RB, Dodge RC, Edwards RP, et al. Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol 2011; 21:188-196.
16. Danforth KN, Tworoger SS, Hecht JL, et al. Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer Causes Control 2007; 18:517-523.
17. Jordan SJ, Siskind V, Green AC, et al. Breastfeeding and risk of epithelial ovarian cancer. Cancer Causes Control 2010; 21:109-116.
18. Zhang M, Xie X, Lee AH, Binns CW. Prolonged lactation reduces ovarian cancer risk in Chinese women. Eur J Cancer Prev 2004; 13:499-502.
19. Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia? Lancet 1971; 2:163.
20. Casagrande JT, Louie EW, Pike MC, et al. 'Incessant ovulation' and ovarian cancer. Lancet 1979; 2:170-173.
21. Godwin AK, Testa JR, Handel LM, et al. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst 1992; 84:592-601.
22. Tung KH, Wilkens LR, Wu AH, et al. Effect of anovulation factors on pre and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol 2005; 161:321-329.
23. Giles JR, Elkin RG, Trevino LS, et al. The restricted ovulator chicken: a unique animal model for investigating the etiology of ovarian cancer. Int J Gynecol Cancer 2010; 20:738-744.
24. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71:717-721.
25. Mohle J, Whittemore A, Pike M, Darby S. Gonadotrophins and ovarian cancer risk. J Natl Cancer Inst 1985; 75:178-180.
26. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1184-1203.
27. Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331:771-776.
28. Shushan A, Paltiel O, Iscovich J, et al. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996; 65:13-18.
29. Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998; 147:1038-1042.
30. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 2004; 103:1194-1203.
31. Jensen A, Sharif H, Frederiksen K, Kjaer SK. Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ 2009; 338:b249.
32. Mosgaard BJ, Lidegaard O, Kjaer SK, et al. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 1997; 67:1005-1012.
33. Rossing MA, Tang MT, Flagg EW, et al. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 2004; 160:1070-1078.
34. Doyle P, Maconochie N, Beral V, et al. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002; 17:2209-2213.
35. Brinton LA, Moghissi KS, Scoccia B, et al. Ovulation induction and cancer risk. Fertil Steril 2005; 83:261-274.
36. Hughes E, Collins J, Vandekerckhove P. Clomiphene citrate for unexplained subfertility in women. Cochrane Database Syst Rev 2000; CD000057.
37. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155:217-224.
38. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1204-1211.
39. Mosgaard BJ, Lidegaard O, Kjaer SK, et al. Ovarian stimulation and borderline ovarian tumors: a case-control study. Fertil Steril 1998; 70: 1049-1055.
40. Sanner K, Conner P, Bergfeldt K, et al. Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertil Steril 2009; 91:1152-1158.
41. Venn A, Watson L, Lumley J, et al. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995; 346:995-1000.
42. Venn A, Watson L, Bruinsma F, et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999; 354:1586-1590.
43. Dor J, Lerner-Geva L, Rabinovici J, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002; 77: 324-327.
44. Lerner-Geva L, Geva E, Lessing JB, et al. The possible association between in vitro fertilization treatments and cancer development. Int J Gynecol Cancer 2003; 13:23-27.
45. Källén B, Finnström O, Nygren KG, et al. In vitro fertilisation in Sweden: obstetric characteristics, maternal morbidity and mortality. BJOG 2005; 112:1529-1535.
46. Yli-Kuha AN, Gissler M, Klemetti R, et al. Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Hum Reprod 2012; 27:1149-1155.
47. van Leeuwen FE, Klip H, Mooij TM, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod 2011; 26:3456-3465.
48. Kurta ML, Moysich KB, Weissfeld JL, et al. Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study. Cancer Epidemiol Biomarkers Prev 2012; 21:1282-1292.
49. Asante A, Leonard PH, Weaver AL, et al. Fertility drug use and the risk of ovarian tumors in infertile women: a case-control study. Fertil Steril 2013; 99:2031-2036.
50. Brinton LA, Trabert B, Shalev V, et al. In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril 2013; 99:1189-1196.
51. Stewart LM, Holman CD, Finn JC, et al. In vitro fertilization is associated with an increased risk of borderline ovarian tumours. Gynecol Oncol 2013; 129:372-376.
52. Stewart LM, Holman CD, Aboagye-Sarfo P, et al. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol 2013; 128:260-264.
53. Siristatidis C, Sergentanis TN, Kanavidis P, et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer - a systematic review and meta-analysis. Hum Reprod Update 2013; 19:105-123.
54. Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am J Clin Pathol 2005; 123 (Suppl):S13-S57.
55. Auranen A, Grénman S, Mäkinen J, et al. Borderline ovarian tumors in Finland: epidemiology and familial occurrence. Am J Epidemiol 1996; 144:548-553.
56. Cusidó M, Balagueró L, Hernandez G, et al. Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol 2007; 104:617-622.